TCGA-CV-7432-01A-11R-2132-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.586757991
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.660
- E2F_TARGETS+0.620
- G2M_CHECKPOINT+0.580
- MYC_TARGETS_V1+0.580
- MTORC1_SIGNALING+0.440
- MITOTIC_SPINDLE+0.380
- PROTEIN_SECRETION+0.370
- CHOLESTEROL_HOMEOSTASIS+0.330
- GLYCOLYSIS+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.230
- ALLOGRAFT_REJECTION-0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.190
- KRAS_SIGNALING_DN-0.180
- MYOGENESIS-0.170
- BILE_ACID_METABOLISM-0.150
- KRAS_SIGNALING_UP-0.150
- IL2_STAT5_SIGNALING-0.130
- INFLAMMATORY_RESPONSE-0.100
- APICAL_SURFACE-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 131484 | EPN | Supratentorial EPN | 0.862 |
| 2 | TCGA-HQ-A5ND-01A-11R-A26T-07 | — | — | 0.861 |
| 3 | TCGA-78-7146-01A-11R-2039-07 | — | cohortA1 | 0.860 |
| 4 | SRR15030865 | — | — | 0.859 |
| 5 | 17-020P2_Bladder | — | — | 0.847 |
| 6 | TCGA-CR-6493-01A-11R-1873-07 | — | — | 0.840 |
| 7 | TCGA-33-4583-01A-01R-1443-07 | — | cohortSQ2 | 0.834 |
| 8 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.827 |
| 9 | TCGA-56-7222-01A-11R-2045-07 | — | cohortSQ1 | 0.826 |
| 10 | 23F34B20-F029-44F5-B3B5-06A74FC0FC9D | — | — | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.660 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.580 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.580 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.230 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |